Trinity, the leader in integrating human and artificial intelligence for life sciences commercialization, has announced it has acquired Verix, the pharma-native commercial intelligence company behind patented, AI-powered Tovana platform. Tovana is live today in global pharma, biotech, and specialty pharma commercial organizations, where it turns prescription, claims, clinical, and engagement data into continuous next-best-action, dynamic targeting, and omnichannel orchestration for brand, field, and digital teams. Acquisition brings Verix's entire team into Trinity and adds AI execution layer to TrinityEDGE.
Pharma has already bought AI but has not yet realized pay off. Trinity's 2025 Commercial and Medical IT benchmark found 100 percent surveyed organizations had adopted generative AI, yet innovation confidence averaged just 3 out of 5, and every respondent described organization as only somewhat prepared to respond rapidly to industry change. Separate benchmark found only 10 percent had clear AI strategy scaling across workflows.
Reason is rarely model. It is distance between insight and moment someone acts on it. Targeting lists go stale between planning cycles. Omnichannel plans degrade. Next-best-action tools get ignored because reps cannot see why trust them. Closing that insight-to-action loop is problem TrinityEDGE with Tovana will solve.
Acquisition advances Trinity growth strategy. Over past three years Trinity augmented advisory and insights services with TrinityEDGE productized commercialization platform adding software, data, and AI alongside 1,500 professionals in 14 offices on five continents. Verix deepens presence with brand, field, and digital buyers and establishes dedicated AI and product development center.
Proof not promise: Tovana developed and validated in live pharma and biotech deployments since 2007 across large global pharma, mid-size biotech, and specialty and rare disease including publicly referenced support for U.S. launch of targeted oncology immunotherapy in market sponsor estimates at more than $400 million.
What clients get: plan that holds up between quarters with targeting updating against what market actually doing, guidance field will actually use sourced and explainable delivered inside field workflow through FieldAdvisor, and one partner instead of two avoiding standing up another vendor.
"Every commercial leader I meet is asking how to put AI to work where it actually changes a call, a channel mix, or a forecast," said Scott Evangelista, Chief Executive Officer of Trinity. "Insight has outpaced execution. Teams are rich in disparate analysis and thin in decisive action in front of a customer. Verix closes that gap. Next-best-action, dynamic targeting, and omnichannel orchestration now sit inside TrinityEDGE, proven in live pharma deployments and backed by 30 years of therapeutic and commercial judgment. That is what it means to lead in integrating human and artificial intelligence for life sciences commercialization."
"We built Verix on one conviction: commercial teams deserve intelligence that is timely, explainable, and usable in the flow of work," said Doron Aspitz, Chief Executive Officer of Verix. "Joining Trinity is the natural next step. Clients keep the product they rely on and gain the launch, access, and competitive context that tells them whether performance is genuinely competitive. I am proud of what our teams have built and energized by what we can now build together."
About Verix
Verix is leading provider of advanced commercial optimization solutions for life sciences industry. Its flagship product Tovana is patented AI-powered SaaS platform integrating advanced machine learning, agentic workflows, and deep domain expertise supporting dynamic targeting, next best action, omnichannel orchestration and forecasting.
About Trinity
Trinity is life sciences commercialization company combining deep therapeutic, functional, and commercial expertise with AI-powered platforms. For more than 30 years pharmaceutical, biotech, and medtech companies have relied on Trinity.
